Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methyldopa
Drug ID BADD_D01425
Description Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent.[A231784] It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals.[A1499] Methyldopa exists in two isomers D-α-methyldopa and L-α-methyldopa, which is the active form.[A232224] First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency. Since then, methyldopa was largely replaced by newer, better-tolerated antihypertensive agents;[A231784] however, it is still used as monotherapy [L32614] or in combination with [hydrochlorothiazide].[L32619] Methyldopa is also available as intravenous injection, which is used to manage hypertension when oral therapy is unfeasible and to treat hypertensive crisis.[L32624]
Indications and Usage For use in the treatment of hypertension.
Marketing Status Prescription; Discontinued
ATC Code C02AB01
DrugBank ID DB00968
KEGG ID D00405
MeSH ID D008750
PubChem ID 38853
TTD Drug ID D0BA6T
NDC Product Code 15894-0038; 42185-7001; 16729-031; 52423-0100; 16729-030; 67628-3001
Synonyms Methyldopa | alpha-Methyldopa | alpha Methyldopa | alpha-Methyl-L-Dopa | alpha Methyl L Dopa | Alphamethyldopa | Meldopa | Methyldopate | Dopegyt | Dopergit | Dopegit | Sembrina | Apo-Methyldopa | Apo Methyldopa | Dopamet | Aldomet | Hydopa | Nu-Medopa | Nu Medopa
Chemical Information
Molecular Formula C10H13NO4
CAS Registry Number 555-30-6
SMILES CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eczema23.03.04.006--
Encephalopathy17.13.02.0010.004706%
Endocrine disorder05.09.01.001--Not Available
Eosinophilia01.02.04.001--
Facial paralysis17.04.03.008--Not Available
Flatulence07.01.04.002--
Gastrointestinal disorder07.11.01.001--Not Available
Granulocytopenia01.02.03.003--Not Available
Gynaecomastia21.05.04.003; 05.05.02.003--
Haemolytic anaemia01.06.03.0020.004706%Not Available
Headache17.14.01.001--
Hepatic cirrhosis09.01.04.0010.001841%Not Available
Hepatic encephalopathy17.13.01.003; 09.01.03.0060.001228%Not Available
Hepatitis09.01.07.004--Not Available
Hepatocellular injury09.01.07.008--Not Available
Hyperbilirubinaemia14.11.01.010; 09.01.01.003; 01.06.04.0030.004706%Not Available
Hyperprolactinaemia05.03.01.002--Not Available
Hypersensitivity10.01.03.003--
Hypertension24.08.02.0010.004706%
Hypertensive crisis24.08.01.0010.004706%Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.004706%
Hypotension24.06.03.0020.007059%
Infection11.01.08.002--Not Available
Jaundice01.06.04.004; 23.03.03.030; 09.01.01.004--Not Available
Joint swelling15.01.02.004--Not Available
LE cells present13.06.01.001--Not Available
Leukopenia01.02.02.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Liver disorder09.01.08.001--Not Available
Liver function test abnormal13.03.01.013--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages